Grufity logo
Grufity logo
IRWD

IRWD - Ironwood Pharmaceuticals Inc Stock Price, Fair Value and News

$4.36+0.05 (+1.16%)
Market Closed as of 17 Aug 2026, 04:00 pm ET

IRWD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IRWD Price Action

Last 7 days

7.7%

Last 30 days

13.0%

Last 90 days

18.8%

Trailing 12 Months

323.3%

IRWD RSI Chart

IRWD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IRWD Valuation

Market Cap

720.4M

Price/Earnings (Trailing)

5.55

Price/Sales (Trailing)

1.85

EV/EBITDA

2.65

Price/Free Cashflow

3.88

IRWD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IRWD Fundamentals

IRWD Revenue

Revenue (TTM)

389.3M

Rev. Growth (Yr)

32.62%

Rev. Growth (Qtr)

6.14%

IRWD Earnings

Earnings (TTM)

129.9M

Earnings Growth (Yr)

117.34%

Earnings Growth (Qtr)

25.8%

IRWD Profitability

Operating Margin

95.09%

EBT Margin

53.27%

Return on Equity

-80.24%

Return on Assets

45.55%

Free Cashflow Yield

25.76%

IRWD Investor Care

Shares Dilution (1Y)

1.73%

Diluted EPS (TTM)

0.77

IRWD Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
Revenue & Growth

How Ironwood Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026361.5M389.3M--
2025317.7M308.5M339.0M296.2M
2024413.6M400.6M378.4M351.4M
2023417.1M427.3M432.4M442.7M
2022422.4M415.6M420.5M410.6M
2021398.4M413.0M413.3M413.8M
2020439.6M426.8M399.1M389.5M
2019346.2M367.3M432.8M428.4M
2018315.3M331.3M310.2M346.6M
2017260.1M270.8M291.5M298.3M
2016186.7M213.3M239.8M274.0M
201590.8M111.7M134.3M149.6M
201434.2M31.4M43.4M76.4M
2013118.4M86.6M54.7M22.9M
201267.9M71.2M155.4M150.2M
2011--50.5M65.9M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Ironwood Pharmaceuticals Inc

IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEironwoodpharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES219

Ironwood Pharmaceuticals Inc Frequently Asked Questions

IRWD is the stock ticker symbol of Ironwood Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Aug 17 2026, market cap of Ironwood Pharmaceuticals Inc is 720.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Aug 17 2026, IRWD's PE ratio (Price to Earnings) is 5.55 and Price to Sales (PS) ratio is 1.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRWD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ironwood Pharmaceuticals Inc has provided -0.091 (multiply by 100 for percentage) rate of return.